The V19L apoA-I mutation, recently identified in Icelanders, is associated with increased HDL-C and decreased CAD risk; rHDL-associated apoA-I(V19L) showed normal capacity to promote ABCA1- and ABCG1-mediated cholesterol efflux, but an increased (45%) ability to promote SR-BI-mediated cholesterol efflux, as a result of the increased ability of apoA-I(V19L) to bind to phospholipids, together with an enhanced thermodynamic stability [90]. The gene discussed is APOA1; the disease is coronary artery disorder.